Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


09.09.2019

1 Ann Surg Oncol
6 BMC Cancer
2 BMJ
4 Br J Cancer
1 Breast Cancer
3 Breast Cancer Res
8 Breast Cancer Res Treat
14 Breast J
1 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
1 Cancer Res
1 Eur J Cancer
2 Gene
1 Int J Cancer
1 Int J Oncol
1 J Biol Chem
1 J Clin Oncol
1 J Nucl Med
2 J Surg Oncol
7 JAMA
3 Lancet
3 Lancet Oncol
1 Nature
1 NPJ Breast Cancer
1 Oncogene
3 Oncol Rep
5 PLoS One
2 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg Oncol

  1. VAN BOMMEL A, van Dalen T
    ASO Author Reflections: Breast Contour-Preserving Procedures as a Means to Address the Esthetic Outcome of Breast Cancer Treatment.
    Ann Surg Oncol. 2019 Sep 4. pii: 10.1245/s10434-019-07770.
    PubMed     Text format    


    BMC Cancer

  2. KIM WH, Kim HJ, Kim SH, Jung JH, et al
    Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: a feasibility study.
    BMC Cancer. 2019;19:859.
    PubMed     Text format     Abstract available

  3. REN ZJ, Cao DH, Zhang Q, Ren PW, et al
    First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:871.
    PubMed     Text format     Abstract available

  4. BAYARMAA B, Wu Z, Peng J, Wang Y, et al
    Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer.
    BMC Cancer. 2019;19:877.
    PubMed     Text format     Abstract available

  5. KRZYZANOWSKA MK, Julian JA, Powis M, Howell D, et al
    Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.
    BMC Cancer. 2019;19:884.
    PubMed     Text format     Abstract available

  6. XIAO B, Chen D, Zhou Q, Hang J, et al
    Glutamate metabotropic receptor 4 (GRM4) inhibits cell proliferation, migration and invasion in breast cancer and is regulated by miR-328-3p and miR-370-3p.
    BMC Cancer. 2019;19:891.
    PubMed     Text format     Abstract available

  7. MCQUERRY JA, Jenkins DF, Yost SE, Zhang Y, et al
    Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes.
    BMC Cancer. 2019;19:881.
    PubMed     Text format     Abstract available


    BMJ

  8. MAHASE E
    Tell women about long term breast cancer risk with HRT, drug agency tells doctors.
    BMJ. 2019;366:l5350.
    PubMed     Text format    

  9. MAHASE E
    Breast cancer risk associated with HRT increases with longer use, finds study.
    BMJ. 2019;366:l5332.
    PubMed     Text format    


    Br J Cancer

  10. CHATTERJEE A, Jana S, Chatterjee S, Wastall LM, et al
    MicroRNA-222 reprogrammed cancer-associated fibroblasts enhance growth and metastasis of breast cancer.
    Br J Cancer. 2019 Sep 4. pii: 10.1038/s41416-019-0566.
    PubMed     Text format     Abstract available

  11. KOGEVINAS M
    Comment on: "Night shift work and risk of breast cancer in women: the Generations Study cohort".
    Br J Cancer. 2019 Sep 5. pii: 10.1038/s41416-019-0567.
    PubMed     Text format    

  12. SAFI N, Anazodo A, Dickinson JE, Lui K, et al
    In utero exposure to breast cancer treatment: a population-based perinatal outcome study.
    Br J Cancer. 2019 Sep 6. pii: 10.1038/s41416-019-0563.
    PubMed     Text format     Abstract available

  13. JONES ME, Schoemaker MJ, McFadden EC, Wright LB, et al
    Reply to Comment on: "Night shift work and risk of breast cancer in women: the Generations Study cohort".
    Br J Cancer. 2019 Sep 5. pii: 10.1038/s41416-019-0568.
    PubMed     Text format    


    Breast Cancer

  14. ANDIC F, Miller AH, Brown G, Chu L, et al
    Instruments for determining clinically relevant fatigue in breast cancer patients during radiotherapy.
    Breast Cancer. 2019 Sep 6. pii: 10.1007/s12282-019-01008.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  15. PATEL TA, Ensor JE, Creamer SL, Boone T, et al
    A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
    Breast Cancer Res. 2019;21:100.
    PubMed     Text format     Abstract available

  16. RIEBENSAHM C, Joosse SA, Mohme M, Hanssen A, et al
    Clonality of circulating tumor cells in breast cancer brain metastasis patients.
    Breast Cancer Res. 2019;21:101.
    PubMed     Text format     Abstract available

  17. MANI C, Jonnalagadda S, Lingareddy J, Awasthi S, et al
    Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Breast Cancer Res. 2019;21:104.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  18. JEON YW, You SH, Lee JE, Youn HJ, et al
    Optimal treatment of breast cancer in women older than 75 years: a Korea Breast Cancer Registry analysis.
    Breast Cancer Res Treat. 2019 Sep 6. pii: 10.1007/s10549-019-05426.
    PubMed     Text format     Abstract available

  19. LAGACE F, Ghazawi FM, Le M, Rahme E, et al
    Analysis of incidence, mortality trends, and geographic distribution of breast cancer patients in Canada.
    Breast Cancer Res Treat. 2019 Sep 4. pii: 10.1007/s10549-019-05418.
    PubMed     Text format     Abstract available

  20. COUGHLIN SS, Caplan LS, Williams V
    Home-based physical activity interventions for breast cancer patients receiving primary therapy: a systematic review.
    Breast Cancer Res Treat. 2019 Sep 6. pii: 10.1007/s10549-019-05424.
    PubMed     Text format     Abstract available

  21. STEENBRUGGEN TG, Bouwer NI, Smorenburg CH, Rier HN, et al
    Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
    Breast Cancer Res Treat. 2019 Sep 6. pii: 10.1007/s10549-019-05427.
    PubMed     Text format     Abstract available

  22. ALFARSI LH, Ansari RE, Craze ML, Toss MS, et al
    CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
    Breast Cancer Res Treat. 2019 Aug 30. pii: 10.1007/s10549-019-05420.
    PubMed     Text format     Abstract available

  23. KACZMAREK E, Saint-Martin C, Pierga JY, Brain E, et al
    Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
    Breast Cancer Res Treat. 2019 Sep 5. pii: 10.1007/s10549-019-05423.
    PubMed     Text format     Abstract available

  24. HOVELING LA, van Maaren MC, Hueting T, Strobbe LJA, et al
    Validation of the online prediction model CancerMath in the Dutch breast cancer population.
    Breast Cancer Res Treat. 2019 Aug 30. pii: 10.1007/s10549-019-05399.
    PubMed     Text format     Abstract available

  25. LI C, Fan H, Xiang Q, Xu L, et al
    Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Aug 30. pii: 10.1007/s10549-019-05421.
    PubMed     Text format     Abstract available


    Breast J

  26. CHO CH, Lee KL, Cho J, Kim D, et al
    The incidence and risk factors of frozen shoulder in patients with breast cancer surgery.
    Breast J. 2019 Sep 6. doi: 10.1111/tbj.13610.
    PubMed     Text format    

  27. THAINEUA V, Ansusinha T, Auamkul N, Taneepanichskul S, et al
    Impact of regular Breast Self-Examination on breast cancer size, stage, and mortality in Thailand.
    Breast J. 2019 Sep 6. doi: 10.1111/tbj.13611.
    PubMed     Text format    

  28. DING DC, Sung FC, Chen W, Wang JH, et al
    Proton pump inhibitors reduce breast cancer risk in gastric ulcer patients: A population-based cohort study.
    Breast J. 2019 Sep 2. doi: 10.1111/tbj.13519.
    PubMed     Text format     Abstract available

  29. MERRILL AL, Smith SM, Peters SB, Agnese DM, et al
    Eccrine carcinoma masquerading as metastatic breast cancer.
    Breast J. 2019 Sep 3. doi: 10.1111/tbj.13543.
    PubMed     Text format    

  30. BARCO I, Garcia-Font M, Garcia-Fernandez A, Gimenez N, et al
    A regression model to predict axillary high tumor burden in sentinel node-positive breast cancer patients.
    Breast J. 2019 Sep 6. doi: 10.1111/tbj.13594.
    PubMed     Text format    

  31. AZORIN SAMPER MDC, Hernandorena Gonzalez M, Ibanez Arias A, Diaz Sierra S, et al
    A case report of pseudoaneurysm after a core needle biopsy of breast cancer.
    Breast J. 2019 Sep 5. doi: 10.1111/tbj.13536.
    PubMed     Text format     Abstract available

  32. FERSTENBERG M, Julian TB
    The ongoing evaluation and evolution of breast cancer surgical care.
    Breast J. 2019 Sep 6. doi: 10.1111/tbj.13526.
    PubMed     Text format     Abstract available

  33. NIXON NA, Simmons C, Lemieux J, Verma S, et al
    Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership.
    Breast J. 2019 Sep 2. doi: 10.1111/tbj.13525.
    PubMed     Text format     Abstract available

  34. KILLELEA BK, Evans SB, Mougalian SS, Gross CP, et al
    Association between perceived benefits and receipt of radiotherapy among older breast cancer patients.
    Breast J. 2019 Sep 3. doi: 10.1111/tbj.13518.
    PubMed     Text format     Abstract available

  35. ALTMAN AM, Nguyen DD, Johnson B, Marmor S, et al
    Intraoperative inking is superior to suture marking for specimen orientation in breast cancer.
    Breast J. 2019 Sep 3. doi: 10.1111/tbj.13508.
    PubMed     Text format     Abstract available

  36. LIAW YY, Loong FS, Tan S, On SY, et al
    A retrospective study on breast cancer presentation, risk factors, and protective factors in patients with a positive family history of breast cancer.
    Breast J. 2019 Sep 4. doi: 10.1111/tbj.13520.
    PubMed     Text format     Abstract available

  37. ELJUGA D, Milas I, Ozretic P, Stanec M, et al
    Prospective study on quality of life after oncoplastic and lumpectomy breast cancer procedures-Is there a difference?
    Breast J. 2019 Sep 4. doi: 10.1111/tbj.13585.
    PubMed     Text format    

  38. BOZKAYA Y, Ay B
    Toxic epidermal necrolysis associated with ribociclib in a patient with metastatic breast cancer.
    Breast J. 2019 Sep 4. doi: 10.1111/tbj.13570.
    PubMed     Text format    

  39. KUMARI S, Malla RR
    Recent advances in metabolomics of triple negative breast cancer.
    Breast J. 2019 Sep 6. doi: 10.1111/tbj.13524.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  40. LIU B, Su F, Lv X, Zhang W, et al
    Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab.
    Cancer Chemother Pharmacol. 2019 Sep 4. pii: 10.1007/s00280-019-03937.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  41. JOHN EM, Canchola AJ, Sanagaramoorthy M, Koo J, et al
    Race/ethnicity and accuracy of self-reported female first-degree family history of breast and other cancers in the Northern California Breast Cancer Family Registry.
    Cancer Epidemiol Biomarkers Prev. 2019 Sep 5. pii: 1055-9965.EPI-19-0444.
    PubMed     Text format     Abstract available


    Cancer Lett

  42. ANDRIEU GP, Shafran JS, Smith CL, Belkina AC, et al
    BET Protein Targeting Suppresses the PD-1/PD-L1 Pathway in Triple-Negative Breast Cancer and Elicits Anti-Tumor Immune Response.
    Cancer Lett. 2019 Aug 29. pii: S0304-3835(19)30450.
    PubMed     Text format     Abstract available

  43. WANG S, Oh DY, Leventaki V, Drakos E, et al
    MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
    Cancer Lett. 2019;465:12-23.
    PubMed     Text format     Abstract available


    Cancer Res

  44. HERMANO E, Goldberg R, Rubinstein AM, Sonnenblick A, et al
    Heparanase accelerates obesity-associated breast cancer progression.
    Cancer Res. 2019 Sep 3. pii: 0008-5472.CAN-18-4058.
    PubMed     Text format     Abstract available


    Eur J Cancer

  45. LLUCH A, Gonzalez-Angulo AM, Casadevall D, Eterovic AK, et al
    Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.
    Eur J Cancer. 2019;120:54-64.
    PubMed     Text format     Abstract available


    Gene

  46. ZOU X, Li M, Huang Z, Zhou X, et al
    Circulating miR-532-502 cluster derived from chromosome X as biomarkers for diagnosis of breast cancer.
    Gene. 2019 Sep 4:144104. doi: 10.1016/j.gene.2019.144104.
    PubMed     Text format     Abstract available

  47. QI L, Yao Y, Zhang T, Feng F, et al
    A four-mRNA model to improve the prediction of breast cancer prognosis.
    Gene. 2019 Sep 4:144100. doi: 10.1016/j.gene.2019.144100.
    PubMed     Text format     Abstract available


    Int J Cancer

  48. KRUGER DT, Alexi X, Opdam M, Schuurman K, et al
    IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
    Int J Cancer. 2019 Sep 6. doi: 10.1002/ijc.32668.
    PubMed     Text format     Abstract available


    Int J Oncol

  49. XIONG Y, Liu Z, Li Z, Wang S, et al
    Long noncoding RNA nuclear paraspeckle assembly transcript 1 interacts with microRNA107 to modulate breast cancer growth and metastasis by targeting carnitine palmitoyltransferase1.
    Int J Oncol. 2019 Sep 4. doi: 10.3892/ijo.2019.4869.
    PubMed     Text format     Abstract available


    J Biol Chem

  50. SOMYAJIT K, Subramanya S, Nagaraju G
    Correction: Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: Implications for Fanconi anemia and breast cancer susceptibility.
    J Biol Chem. 2019;294:13198.
    PubMed     Text format    


    J Clin Oncol

  51. VISVANATHAN K, Fabian CJ, Bantug E, Brewster AM, et al
    Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.
    J Clin Oncol. 2019 Sep 3:JCO1901472. doi: 10.1200/JCO.19.01472.
    PubMed     Text format     Abstract available


    J Nucl Med

  52. RAMOS N, Baquero J, Gironda Z, Zaim-Wadghiri Y, et al
    Non invasive PET imaging of CDK4/6 activation in Breast Cancer.
    J Nucl Med. 2019 Sep 3. pii: jnumed.119.232603. doi: 10.2967/jnumed.119.232603.
    PubMed     Text format     Abstract available


    J Surg Oncol

  53. EBNER PJ, Liu A, Gould DJ, Patel KM, et al
    Breast implant-associated anaplastic large cell lymphoma, a systematic review and in-depth evaluation of the current understanding.
    J Surg Oncol. 2019;120:573-577.
    PubMed     Text format     Abstract available

  54. MURPHY BL, Thiels CA, Hanson KT, McLaughlin S, et al
    Pain and opioid prescriptions vary by procedure after breast surgery.
    J Surg Oncol. 2019;120:593-602.
    PubMed     Text format     Abstract available


    JAMA

  55. PACE LE, Keating NL
    Medications to Reduce Breast Cancer Risk: Promise and Limitations.
    JAMA. 2019;322:821-823.
    PubMed     Text format    

  56. JIN J
    Medications to Reduce Breast Cancer Risk.
    JAMA. 2019;322:900.
    PubMed     Text format    

  57. NELSON HD, Fu R, Zakher B, Pappas M, et al
    Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2019;322:868-886.
    PubMed     Text format     Abstract available

  58. OWENS DK, Davidson KW, Krist AH, Barry MJ, et al
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2019;322:652-665.
    PubMed     Text format     Abstract available

  59. OWENS DK, Davidson KW, Krist AH, Barry MJ, et al
    Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2019;322:857-867.
    PubMed     Text format     Abstract available

  60. NELSON HD, Pappas M, Cantor A, Haney E, et al
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2019;322:666-685.
    PubMed     Text format     Abstract available

  61. JIN J
    Should I Be Tested for BRCA Mutations?
    JAMA. 2019;322:702.
    PubMed     Text format    


    Lancet


  62. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31709.
    PubMed     Text format     Abstract available

  63. BERAL V, Peto R, Pirie K, Reeves G, et al
    Menopausal hormone therapy and 20-year breast cancer mortality.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)32033.
    PubMed     Text format    

  64. KOTSOPOULOS J
    Menopausal hormones: definitive evidence for breast cancer.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31901.
    PubMed     Text format    


    Lancet Oncol

  65. GOURD E
    Pyrotinib versus lapatinib in HER2-positive breast cancer.
    Lancet Oncol. 2019 Aug 30. pii: S1470-2045(19)30568.
    PubMed     Text format    

  66. NAROD SA
    MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc).
    Lancet Oncol. 2019;20:e465.
    PubMed     Text format    

  67. ZOLNIKOV TR, Chambers D
    Barriers to treatment for patients with breast cancer in Kenya.
    Lancet Oncol. 2019;20:1206-1207.
    PubMed     Text format    


    Nature

  68. PADMANABAN V, Krol I, Suhail Y, Szczerba BM, et al
    E-cadherin is required for metastasis in multiple models of breast cancer.
    Nature. 2019 Sep 4. pii: 10.1038/s41586-019-1526.
    PubMed     Text format     Abstract available


    NPJ Breast Cancer

  69. GUPTA S, Neumeister V, McGuire J, Song YS, et al
    Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer.
    NPJ Breast Cancer. 2019;5:28.
    PubMed     Text format     Abstract available


    Oncogene

  70. LU X, Liu R, Wang M, Kumar AK, et al
    MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer.
    Oncogene. 2019 Aug 30. pii: 10.1038/s41388-019-0986.
    PubMed     Text format     Abstract available


    Oncol Rep

  71. CHEN P, Feng Y, Zhang H, Shi X, et al
    MicroRNA192 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting caveolin 1.
    Oncol Rep. 2019 Aug 30. doi: 10.3892/or.2019.7298.
    PubMed     Text format     Abstract available

  72. ZHANG W, Xu J, Wang K, Tang X, et al
    miR1393p suppresses the invasion and migration properties of breast cancer cells by targeting RAB1A.
    Oncol Rep. 2019 Aug 29. doi: 10.3892/or.2019.7297.
    PubMed     Text format     Abstract available

  73. WANG Z, Zhang M, Shan R, Wang YJ, et al
    MTMR3 is upregulated in patients with breast cancer and regulates proliferation, cell cycle progression and autophagy in breast cancer cells.
    Oncol Rep. 2019 Aug 23. doi: 10.3892/or.2019.7292.
    PubMed     Text format     Abstract available


    PLoS One

  74. SATOMI-TSUSHITA N, Shimomura A, Matsuzaki J, Yamamoto Y, et al
    Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer.
    PLoS One. 2019;14:e0222024.
    PubMed     Text format     Abstract available

  75. LU Y, Zhang L, Zhang Q, Zhang Y, et al
    The association of D-dimer with clinicopathological features of breast cancer and its usefulness in differential diagnosis: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0221374.
    PubMed     Text format     Abstract available

  76. ABDEL-FATTAH M, Saeed H, El-Shennawy L, Shalaby M, et al
    The Arabian camel, Camelus dromedarius interferon epsilon: Functional expression, in vitro refolding, purification and cytotoxicity on breast cancer cell lines.
    PLoS One. 2019;14:e0213880.
    PubMed     Text format     Abstract available

  77. SCHAFFAR R, Bouchardy C, Chappuis PO, Bodmer A, et al
    A population-based cohort of young women diagnosed with breast cancer in Geneva, Switzerland.
    PLoS One. 2019;14:e0222136.
    PubMed     Text format     Abstract available

  78. BROUWER A, De Laere B, van Dam PJ, Peeters D, et al
    HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques.
    PLoS One. 2019;14:e0220906.
    PubMed     Text format     Abstract available


    Radiology

  79. COLIN C, Doutriaux-Dumoulin I
    Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities.
    Radiology. 2019 Sep 3:191306. doi: 10.1148/radiol.2019191306.
    PubMed     Text format    

  80. JOHNSON K, Zackrisson S, Rosso A, Sartor H, et al
    Tumor Characteristics and Molecular Subtypes in Breast Cancer Screening with Digital Breast Tomosynthesis: The Malmo Breast Tomosynthesis Screening Trial.
    Radiology. 2019 Sep 3:190132. doi: 10.1148/radiol.2019190132.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: